ES2156199T3 - Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma. - Google Patents

Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.

Info

Publication number
ES2156199T3
ES2156199T3 ES95308055T ES95308055T ES2156199T3 ES 2156199 T3 ES2156199 T3 ES 2156199T3 ES 95308055 T ES95308055 T ES 95308055T ES 95308055 T ES95308055 T ES 95308055T ES 2156199 T3 ES2156199 T3 ES 2156199T3
Authority
ES
Spain
Prior art keywords
interferon
gamma
prevention
treatment
polipeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95308055T
Other languages
English (en)
Other versions
ES2156199T5 (es
Inventor
Shimpei Ushio
Kakuji Torigoe
Tadao Tanimoto
Haruki Okamura
Toshio Kunikata
Mutsuko Taniguchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Hayashibara Biochemical Laboratories Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27523434&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2156199(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP7058240A external-priority patent/JP2952750B2/ja
Priority claimed from JP7262062A external-priority patent/JP2724987B2/ja
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK, Hayashibara Biochemical Laboratories Co Ltd filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Application granted granted Critical
Publication of ES2156199T3 publication Critical patent/ES2156199T3/es
Publication of ES2156199T5 publication Critical patent/ES2156199T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UN POLIPEPTIDO QUE TIENE UN PESO MOLECULAR DE 18,500 (MAS MENOS) 3,000 DALTONS EN SDS-PAGE Y UN PL DE 4.9 (MAS MENOS) 1.0 SOBRE CROMATOENFOCADO. EL POLIPEPTIDO INDUCE FUERTEMENTE LA PRODUCCION DE IFN-{GA} POR CELULAS INMUNOCOMPETENTES CON SOLAMENTE UNA PEQUEÑA CANTIDAD, Y NO PROVOCA SERIOS EFECTOS COLATERALES INCLUSO CUANDO SE ADMINISTRA A LOS HUMANOS EN UNAS DOSIS RELATIVAMENTE ALTAS. SE PREPARA UTILIZANDO UN ANTICUERPO MONOCLONAL OBTENIDO A PARTIR DE HIBRIDOMAS, Y SE INCORPORA EN AGENTES PARA EL TRATAMIENTO Y/O LA PREVENCION DE TUMORES MALIGNOS, ENFERMEDADES VIRALES, ENFERMEDADES POR INFECCION BACTERIANA Y ENFERMEDADES INMUNES.
ES95308055T 1994-11-15 1995-11-10 Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma. Expired - Lifetime ES2156199T5 (es)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP30420394 1994-11-15
JP6-304203 1994-11-15
JP7058240A JP2952750B2 (ja) 1995-02-23 1995-02-23 モノクローナル抗体
JP7-58240 1995-02-23
JP7-78357 1995-03-10
JP7835795 1995-03-10
JP7-262062 1995-09-18
JP7262062A JP2724987B2 (ja) 1994-11-15 1995-09-18 インターフェロン−γの産生を誘導するポリペプチド
JP27498895 1995-09-29
JP7-274988 1995-09-29

Publications (2)

Publication Number Publication Date
ES2156199T3 true ES2156199T3 (es) 2001-06-16
ES2156199T5 ES2156199T5 (es) 2006-12-16

Family

ID=27523434

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99104104T Expired - Lifetime ES2329099T3 (es) 1994-11-15 1995-11-10 Fragmento polipeptidico aislado que induce produccion de interferon-gamma y un fragmento de adn aislado que codifica dicho polipeptido.
ES95308055T Expired - Lifetime ES2156199T5 (es) 1994-11-15 1995-11-10 Polipeptido inductor de la produccion de interferon-gamma, anticuerpos monoclonales y composicion para el tratamiento o la prevencion de enfermedades sensibles al interferon-gamma.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES99104104T Expired - Lifetime ES2329099T3 (es) 1994-11-15 1995-11-10 Fragmento polipeptidico aislado que induce produccion de interferon-gamma y un fragmento de adn aislado que codifica dicho polipeptido.

Country Status (7)

Country Link
EP (2) EP0962531B1 (es)
AU (1) AU700948B2 (es)
CA (1) CA2162353C (es)
DE (2) DE69535989D1 (es)
DK (2) DK0962531T3 (es)
ES (2) ES2329099T3 (es)
TW (2) TW581771B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
US7135458B1 (en) 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
CA2238885A1 (en) * 1995-12-29 1997-07-10 Incyte Pharmaceuticals, Inc. Nucleic acids encoding interferon gamma inducing factor-2
CA2255906A1 (en) * 1996-05-20 1997-11-27 Schering Corporation Human interleukin-1j and antagonists thereof
US6060283A (en) * 1996-06-27 2000-05-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
US6790442B1 (en) 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
JPH1080270A (ja) * 1996-07-19 1998-03-31 Hayashibara Biochem Lab Inc ポリペプチドをプロセッシングする酵素
TW515843B (en) * 1996-07-25 2003-01-01 Hayashibara Biochem Lab Process for producing an active polypeptide inducing interferon-γ production
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US7141393B2 (en) 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
JP3955352B2 (ja) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
US6087116A (en) 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
EP1013763B1 (en) * 1997-08-07 2011-02-02 Toray Industries, Inc. Canine interleukin 18 production method
WO1999022760A1 (en) * 1997-11-03 1999-05-14 The Wistar Institute Of Anatomy And Biology Method and compositions for inhibiting angiogenesis and treating cancer
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
RU2175554C2 (ru) * 1999-03-30 2001-11-10 Пермское научно-производственное объединение "Биомед" Оральный препарат интерферона в виде таблеток
US6432678B1 (en) * 1999-06-21 2002-08-13 Smithkline Beecham Corporation Macaca cynomolgus IL 18
PL356836A1 (en) 2000-02-10 2004-07-12 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
GB0009503D0 (en) * 2000-04-17 2000-06-07 Univ Liverpool Screening method for compounds
CN1457258A (zh) * 2000-06-02 2003-11-19 史密丝克莱恩比彻姆公司 用il－18和il－18组合物治疗病毒性疾病的方法
PL366134A1 (en) 2000-06-15 2005-01-24 Smithkline Beecham Corporation Method for preparing a physiologically active il-18 polypeptide
CA2451955C (en) 2001-06-26 2015-09-29 Abgenix, Inc. Antibodies to opgl
US20040023336A1 (en) * 2001-10-26 2004-02-05 Heavner George A. Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses
WO2004060911A2 (en) 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
TW200510454A (en) 2003-04-15 2005-03-16 Smithkline Beecham Corp Conjugates comprising human IL-18 and substitution mutants thereof
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
PL1793859T3 (pl) 2004-08-20 2009-08-31 Smithkline Beecham Corp Leczenie zapalenia śluzówki jamy ustnej i jelit przez podawanie ludzkiej IL-18
AU2007267213B2 (en) 2006-05-25 2012-03-29 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
AR065803A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
US8168165B2 (en) 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
US20120308564A1 (en) 2010-02-09 2012-12-06 Andrew Ian Bayliffe Treatment of a metabolic disorder
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
KR101940430B1 (ko) 2014-08-07 2019-01-18 가꼬우호우징 효고 이카다이가쿠 Il-18과 분자 표적 항체를 병용하는 암 치료약

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
JP3230531B2 (ja) * 1991-08-08 2001-11-19 光信 佐藤 ＩＦＮ―γ誘導活性物質
DE69519454T2 (de) * 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen

Also Published As

Publication number Publication date
DK0962531T3 (da) 2009-10-05
CA2162353C (en) 2010-04-27
AU700948B2 (en) 1999-01-14
EP0712931B1 (en) 2001-02-14
DE69520088T3 (de) 2006-11-23
EP0962531A2 (en) 1999-12-08
DE69520088D1 (de) 2001-03-22
AU3779695A (en) 1996-05-23
ES2156199T5 (es) 2006-12-16
DE69535989D1 (de) 2009-09-17
TW581771B (en) 2004-04-01
TW464656B (en) 2001-11-21
ES2329099T3 (es) 2009-11-20
EP0962531A3 (en) 1999-12-15
DK0712931T4 (da) 2006-08-21
EP0712931B2 (en) 2006-04-19
DK0712931T3 (da) 2001-03-19
DE69520088T2 (de) 2004-07-29
CA2162353A1 (en) 1996-05-16
EP0962531B1 (en) 2009-08-05
EP0712931A3 (en) 1997-03-26
EP0712931A2 (en) 1996-05-22

Similar Documents

Publication Publication Date Title
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
BR9915852A (pt) Conjugado de hapteno-portador para tratamento e prevenção do vìcio da nicotina
IL104696A0 (en) Dual carrier immunogenic construct and a vaccine containing the same
PT1187629E (pt) Composicao adjuvante que compreende saponina e um oligonucleotido imunoestimulador
ES2179105T3 (es) Adyuvantes proteinicos.
EP0090581A3 (en) Small peptides with the specificity of foot and mouth disease viral antigens
DK0588578T3 (da) Immunogener
ES2075440T3 (es) Vacuna contra la hepatitis b.
CY1108147T1 (el) Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων
BR0212556A (pt) interleucina-12 como um adjuvante de vacina veterinária
ATE265535T1 (de) Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
DE68918761D1 (de) Therapeutische IgM-Konzentrate.
DE69126486D1 (de) Induzierung eines schutzes gegen virale infektionen
NZ316970A (en) Viral recombinant pseudo-particles and vaccinal and anti-tumoral applications
ATE133074T1 (de) Verwendung von il-4 zur verstärkung der immunantwort auf infektiöse antigen- herausforderungen
JPS5668615A (en) Ricin-containing agent for immunological enhancement
Gotohda et al. Effect of combination treatment with cyclophosphamide and nonspecific passive immunization on a transplantable tumor in WKA rats
KR890017363A (ko) 스트로빌루린 유도체, 이들의 제법 및 용도
ATE145335T1 (de) Kreuzreaktive immunisierung gegen influenza
SU1739559A1 (ru) Штамм вируса aphtae epizooticae типа o, используемый для изготовления диагностических сывороток и антигенных препаратов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 712931

Country of ref document: ES